Results 141 to 150 of about 3,323,629 (269)

Sexual function after prostate cancer surgery or radiotherapy in an international registry

open access: yesBJU International, Volume 138, Issue 6, Page 1092-1103, December 2026.
Objectives Our objective was to evaluate patient‐reported sexual function (SF) outcomes and sexual aid use 12 months after curative treatment for prostate cancer (PC). Patients & Methods This prospective registry‐based cohort study analysed men with localized or locally advanced PC enrolled in the TrueNTH Global Registry.
Y. Hess‐Busch   +10 more
wiley   +1 more source

Musculoskeletal health in prostate cancer patients treated with androgen deprivation therapy: a review of current practice guidelines

open access: yes, 2013
Musculoskeletal health in prostate cancer patients treated with androgen deprivation therapy: a review of current practice ...
Trish Livingston (13098306)   +3 more
core  

The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer

open access: yesBJU International, Volume 138, Issue 6, Page 1013-1024, December 2026.
Objectives Primary objective: to determine whether prostate gland partial ablation (PA) has non‐inferior oncological treatment success vs radical treatment (RT) of localised intermediate‐risk prostate cancer (irPCa). Secondary objectives: to compare (i) participant‐reported urinary and sexual dysfunction side effects, (ii) short/medium term serious ...
Richard J. Bryant   +42 more
wiley   +1 more source

UPDATE ON ANDROGEN DEPRIVATION THERAPY AND ADJUVANT METFORMIN (ADMET) TRIAL FOR MEN WITH TREATMENT NAIVE METASTATIC PROSTATE CANCER

open access: yes, 2016
UPDATE ON ANDROGEN DEPRIVATION THERAPY AND ADJUVANT METFORMIN (ADMET) TRIAL FOR MEN WITH TREATMENT NAIVE METASTATIC PROSTATE ...
J Gunter (13754467)   +8 more
core  

Accessing and Navigating Gender‐Affirming Hormone Therapy and Perspectives on Inclusive Pharmacy Care Among Transgender and Gender Diverse People: A Qualitative Study

open access: yesHealth Expectations, Volume 29, Issue 6, December 2026.
ABSTRACT Introduction Transgender and gender diverse (TGD) people continue to experience inequities in access to gender‐affirming care, including stigmatisation, delayed treatment and non‐inclusive healthcare encounters. Community pharmacies may represent an accessible setting to support inclusive and affirming care; however, lived experiences of ...
Jessica McCann   +5 more
wiley   +1 more source

The Boron–Neuron Connection: The Potential of Boron‐Containing Molecules for Treating Incurable Amyotrophic Lateral Sclerosis

open access: yesChemMedChem, Volume 21, Issue 21, 12 November 2026.
Can a single element help address the multifactorial nature of ALS? Boron‐containing compounds combine responsiveness to reactive oxygen species (ROS), neuroprotective activity, and favorable pharmacological properties, offering a distinctive framework for disease modification in a complex disease like ALS.
Nitesh Sanghai   +5 more
wiley   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2896-2917, November 2026.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: A systematic review

open access: yes, 2014
Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: A systematic ...
Trish Livingston (13098306)   +2 more
core  

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2699-2717, November 2026.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy